December 11, 2019

MICHAEL T. BROWN
PROVOST AND EXECUTIVE VICE PRESIDENT
UNIVERSITY OF CALIFORNIA

Re: Approval of Pre-Proposal for UCI School of Pharmacy and Pharmaceutical Sciences

Dear Michael,

In accordance with the Universitywide Review Processes For Academic Programs, Units, and Research Units (the “Compendium”), the Academic Senate solicited input from the Coordinating Committee on Graduate Affairs (CCGA), the University Committee on Planning and Budget (UCPB), and the University Committee on Educational Policy (UCEP), regarding the UC Irvine pre-proposal to establish a School of Pharmacy and Pharmaceutical Sciences.

The Senate’s three Compendium Committees agree that UCI’s pre-proposal is worthy of continued development, but they have also identified several significant concerns that should be addressed in the full proposal. The Committees’ reviews are attached. We look forward to reviewing the full proposal in the future.

Please do not hesitate to contact me if you have additional questions.

Sincerely,

Kum-Kum Bhavnani, Chair
Academic Council

cc: Academic Council
    UCI Assistant Senate Director Anzivino
    Chief of Staff to the Provost Peterson
    IRAP Analyst Procello
ACADEMIC COUNCIL CHAIR KUM-KUM BHAVNANI

Dear Kum-Kum,

At its November 6 meeting, the Coordinating Committee on Graduate Affairs (CCGA) voted 10-0-1 to approve a pre-proposal for a new School of Pharmacy and Pharmaceutical Sciences on the Irvine campus.

UCI has planned for more than a decade to establish a school of pharmacy; the proposed school will focus on integrative and interdisciplinary research and training in basic and clinical pharmacy, with particular emphasis on preventive measures and/or alternatives to standard medications and healthcare practices. Educational programs in the school are planned to include a new Doctor of Pharmacy (Pharm.D.) degree, concurrently proposed; the pre-existing Ph.D., master’s, and bachelor’s programs; and the addition of a second Self-Supporting Graduate Professional Degree Program (SSGPDP). The school also offers a post-baccalaureate certificate program and plans to establish a robust program of professional training opportunities that offer continuing education units to practicing pharmacists.

The Ph.D. in Pharmacological Sciences program prepares students for careers in academic research institutions, biotechnology and pharmaceutical industries, federal and state agencies, and private research institutions by providing a research-intensive approach to the study of 15 pharmacology and other pharmaceutical sciences. Students applying to the Ph.D. program may choose from among three program concentrations: pharmacology, medicinal chemistry, or pharmaceutical sciences, which all are designed to accommodate the interests of as many potential students as possible.

The inclusion of the school within the Susan and Henry Samueli College of Health Sciences (SHSCOHS) creates rich opportunities for faculty and students to collaborate in education, research, and clinical practice. Healthcare of the future emphasizes teams of physicians, nurses, pharmacists, and public health specialists working together; therefore, the education and training of future practitioners requires training within an interprofessional model.

The pre-proposal is thoughtful and well put together. The CCGA lead reviewer identified three major concerns, which have been highlighted in several aspects of the review process both at UCI and
systemwide. These concerns are elucidated in the attached report. CCGA would like to see those points addressed in a revised full proposal submission.

CCGA recommends approval of this pre proposal with the improvements stipulated. I submit this for your review and have enclosed my report as Lead Reviewer. Please do not hesitate to contact me if you have further questions regarding the proposal.

Sincerely,

[Signature]

Ramesh Balasubramaniam
Chair, Coordinating Committee on Graduate Affairs (CCGA)

cc: Mary Gauvain, Academic Council Vice Chair
CCGA Members
Hilary Baxter, Academic Senate Executive Director
Michael LaBriola, Academic Senate Associate Director
Chris Procello, Academic Planning and Research Analyst
Gillian Hayes, UC Irvine Graduate Dean
Kate Brigman, UCI Senate Executive Director
Thao Nguyen, UCI Senate Analyst

Enclosures (1)
The Susan and Henry Samueli College of Health Sciences will house the School of Pharmacy and Pharmaceutical Sciences. The school will be established from an existing Department of Pharmaceutical Sciences that currently administers a Ph.D. in Pharmacological Sciences with concentrations in pharmacology, medicinal chemistry, and pharmaceutical sciences, a Doctor of Medicine (M.D./Ph.D. in Pharmacological Sciences), a self-supporting Master of Science in Pharmacology, a Bachelor of Science in Pharmaceutical Sciences, and a Post-Baccalaureate Certificate in Pharmaceutical Sciences. The school has plans to offer a new Doctor of Pharmacy (Pharm.D.) program, along with a second self-supporting master’s degree program. This second self-supporting master’s program has a planned start date of Fall 2022 with a focus on translational research and/or applications of the pharmaceutical sciences across the broad landscape of medication utilization and pharmacy practice.

The pre-proposal is thoughtful and well put together. The CCGA lead reviewer identified three major concerns, which have been highlighted in several aspects of the review process both at UCI and systemwide.

1) As stated in CCGA’s review criteria for new programs (and schools that house them), a statement and plan of the School’s vision for Diversity, equity, and inclusion will be necessary.
   “All proposals must include (a) a vision for how the program will advance UC’s goals for diversity and (b) a plan that details what steps the program will take in its first five years to move it toward the identification, recruitment, and retention of underrepresented minority students and faculty. The proposal should will evaluate its diversity goals.”

2) Although this is likely to be addressed when the new programs are reviewed, CCGA encourages the proposers to think about the impact that the self-supported programs will have on the school’s resources and state supported students. Of particular concern are issues related to the diversity of the student body in the self and state supported programs.

3) The growth plan from ~45 PhD students to nearly double that in 2026 needs to be thought through carefully. It is not clear if adequate funds are budgeted for this (both on the revenue and expenditure side) so the quality of the program offerings can be maintained.

CCGA would like to see the above points addressed in a revised full proposal submission.

Ramesh Balasubramaniam
Chair, CCGA
Lead Reviewer, UCI School of Pharm pre-proposal
KUM-KUM BHAVNANI, CHAIR
ACADEMIC COUNCIL

RE: UC Irvine’s pre-proposal to establish a School of Pharmacy & Pharmaceutical Sciences

Dear Kum-Kum,

UCPB has reviewed UC Irvine’s pre-proposal to establish a School of Pharmacy & Pharmaceutical Sciences.

In general, UCPB found that the pre-proposal provides appropriate and adequate detail for this review stage, and satisfactorily addresses the four Compendium review categories for new schools: academic rigor, financial viability, need, and fit within the UC system and the segments. UCPB also identified several critical issues we hope the final proposal will address and clarify, summarized in the attached report. UCPB looks forward to evaluating the full proposal when it is ready.

Sincerely,

Sean Malloy, Chair
UCPB

Encl.

cc: UCPB
UCPB Review of UCI Pre-Proposal for School of Pharmacy and Pharmaceutical Sciences

The proposed School would be based in the Susan and Henry Samueli College of Health Sciences and be supported by existing faculty, the $200M Sameuli gift, and additional funds provided by the provost. The overall objective is to position the School to comprehensively address professional training in pharmacy and pharmaceutical sciences. Currently, this College is home to a Department of Pharmaceutical Sciences that administers a Ph.D. in Pharmacological Sciences with concentrations in pharmacology, medicinal chemistry, and pharmaceutical sciences, a Doctor of Medicine (M.D./Ph.D. in Pharmacological Sciences), a self-supporting Master of Science in Pharmacology, a Bachelor of Science in Pharmaceutical Sciences, and a Post-Baccalaureate Certificate in Pharmaceutical Sciences. The proposed new School would include these existing programs PLUS: 1) a new Doctor of Pharmacy (Pharm.D.) program (that requires a School of Pharmacy for accreditation purposes); and 2) a second self-supporting master’s degree program (SSGPDP). This second master’s program would commence in Fall 2022 and focus on translational research/applications of the pharmaceutical sciences across the broad landscape of medication utilization and pharmacy practice.

There are several issues the full proposal should address more explicitly:

1. Masters programs are rarely self-supporting. What is the evidence that the current Master of Science in Pharmacology is self-supporting? Without a specific educational focus, how can UCI be confident that a second Masters program will be self-supporting? What is the rationale for proposing a second Masters program at this time?
2. There has been an increase in the number of schools offering Pharm.D. degrees over the past several decades accompanied by a decline in jobs for Pharm.D. graduates (the ratio of applicants to slots is approaching 1:1). Thus, what is the evidence that there is a qualified applicant pool for a new Pharm.D. program at UCI given the large number of extant programs in the US and California?
3. What are the contingency plans if the targeted $4.6 million of philanthropic support cannot be raised?
4. How will the enhanced enrollment into the Ph.D. program be supported without additional resources?
5. What is the precise allocation of the $200M gift from the Samuelis to be dedicated to supporting the SPPS (since this resource is also being used to support other efforts of the four schools)?
6. How will the M.D./Ph.D. in Pharmacological Sciences will be integrated with other M.D./Ph.D. programs on the UCI campus, including the NIH-supported MSTP program?

The full proposal should address the concerns/requests for additional information outlined by the UCI Provost in his letter of September 13th, 2019 including: 1) careful attention to implementation to avoid disrupting educational services to students enrolled in programs that will be consolidated under the auspices of the new school; 2) the importance of diversity in hiring new faculty and staff and recruiting new students with explicitly defined diversity goals and a plan for evaluating these goals; and 3) specific and transparent budget analysis and planning regarding: 1) carryforward funds and the reserve balance; and 2) issues around compensation (e.g. the precise compensation plan/program, HSCP versus NSTP, and plans to transition 9-month FTEs to 11-month appointments).
December 2, 2019

KUM-KUM BHAVNANI, CHAIR
ACADEMIC COUNCIL

RE: UCI’S PRE-PROPOSAL FOR A SCHOOL OF PHARMACY & PHARMACEUTICAL SCIENCES

Dear Kum-Kum,

UCEP discussed UCI’s pre-proposal for a School of Pharmacy & Pharmaceutical Sciences (SPPS) during our December 2nd meeting. The committee appreciates that development of the SPPS has been on UCI’s formal Five-year Planning Perspective since 2009 and is a priority in the university’s current strategic plan. The committee understands that the proposed SPPS will encompass existing programs and degrees at UCI and that its establishment will allow the division to offer the PharmD degree, a professional degree approved by the Accreditation Council on Pharmacy Education. We also recognize the various benefits that will result from establishment of the SPPS. UCEP does recommend that the full proposal should comprehensively address the following issues:

1. The development and implementation of the new SPPS and PharmD program along with the current activities of the Department of Pharmaceutical Sciences will necessitate substantial workload including hiring of additional faculty, new roles for existing faculty, curriculum development and implementation, recruitment and retention of students, and developmental of substantial clinical application. How this will be achieved within a tight timeframe should be clarified.

2. The plan for hiring faculty with a primary focus on hiring diverse faculty may not meet timing for curriculum development and implementation and how this is to be accomplished should be explained.

3. It is not clear why multiple programs are needed as this will likely exhaust human resources given numbers of enrollees planned for the multiple programs and the full proposal should include a rationale.

UCEP appreciates the opportunity to comment on this matter and we look forward to receiving the full proposal from UCI. Please contact me if you have any questions.

Sincerely,

John Serences, Chair
UCEP